Immunic Inc
NASDAQ:IMUX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Immunic Inc
Common Shares Outstanding
Immunic Inc
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immunic Inc
NASDAQ:IMUX
|
Common Shares Outstanding
$120.4m
|
CAGR 3-Years
45%
|
CAGR 5-Years
42%
|
CAGR 10-Years
65%
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Common Shares Outstanding
€251.3m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Common Shares Outstanding
€224.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Common Shares Outstanding
€134.1m
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Common Shares Outstanding
€39.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
|
Formycon AG
XETRA:FYB
|
Common Shares Outstanding
€17.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
Immunic Inc
Glance View
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 55 full-time employees. The company went IPO on 2014-04-17. The firm is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The firm is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.
See Also
What is Immunic Inc's Common Shares Outstanding?
Common Shares Outstanding
120.4m
USD
Based on the financial report for Dec 31, 2025, Immunic Inc's Common Shares Outstanding amounts to 120.4m USD.
What is Immunic Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
65%
Over the last year, the Common Shares Outstanding growth was 34%. The average annual Common Shares Outstanding growth rates for Immunic Inc have been 45% over the past three years , 42% over the past five years , and 65% over the past ten years .
